Affiliation:
1. Department of Endocrinology and Metabolism, Xichang People’s
Hospital, Xichang, China
Abstract
AbstractGlycemic variability (GV) has been related to complications in patients with
diabetes. The aim of the systematic review and meta-analysis was to investigate
whether GV is also associated with the incidence of diabetic peripheral
neuropathy (DPN). A systematic search of Medline, Web of Science, Embase, and
Cochrane Library database was conducted to identify relevant observational
studies with longitudinal follow-up. The Newcastle-Ottawa Scale was used for
study quality evaluation. A random-effects model was utilized to pool the
results, accounting for heterogeneity. Ten observational studies including 72
565 patients with diabetes were included. The quality score was 8–9,
indicating generally good quality of the included studies. With a mean follow-up
duration of 7.1 years, 11 532 patients (15.9%) were diagnosed as DPN.
Compared to patients with low GV, patients with high GV were associated with an
increased risk incidence of DPN (risk ratio: 1.51, 95% confidence
interval: 1.23 to 1.85, p<0.001; I2=78%). In addition,
subgroup analysis showed consistent results in patients with type 1 and type 2
diabetes, and in studies evaluating the short-term and long-term GV (p for
subgroup difference=0.82 and 0.53). Finally, results of subgroup
analysis also suggested that the association between GV and risk of DPN were not
significantly affected by study design, follow-up durations, diagnostic methods
for DPN, adjustment of mean glycated hemoglobin A1c, or study quality scores (p
for subgroup difference all>0.05). A high GV may be associated with an
increased incidence of DPN.
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,General Medicine,Endocrinology, Diabetes and Metabolism
Reference36 articles.
1. 12. Retinopathy, neuropathy, and foot care: standards of care in
diabetes-2023;N A ElSayed;Diabetes Care,2023
2. Diabetic peripheral neuropathy: advances in diagnosis and strategies for
screening and early intervention;D Selvarajah;Lancet Diabetes Endocrinol,2019
3. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor
peripheral neuropathy;G Sloan;Nat Rev Endocrinol,2021
4. Disease-specific quality of life in patients with diabetic neuropathy;M Alghamdi;Saudi Med J,2022
5. Towards prevention of diabetic peripheral neuropathy: clinical presentation,
pathogenesis, and new treatments;M A Elafros;Lancet Neurol,2022